Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAP Regimen for Stem Cell Mobilization in Hematological Malignancies
NCT05510089Unknown
- Sponsor
- The Affiliated People’s Hospital of Ningbo University
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of etoposide, cytarabine and pegfilgrastim in multiple myeloma (MM) and lymphoma, sponsored by The Affiliated People’s Hospital of Ningbo University. Primary endpoint: Percentage of patients achieving the collection of >=2x10^6 CD34+ cells/kg at 4 weeks. Status: unknown.
02
Drugs
etoposidecytarabinepegfilgrastim
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NCT05510089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510089.